Your session is about to expire
← Back to Search
Behavioural Intervention
Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia (FH-ALERT Trial)
N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* ≥ 18 years old
* seen in the BWH Endocrinology, Cardiovascular Medicine, and Primary Care Clinics
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Familial Hypercholesterolemia. The main question it aims to answer is whether the computer alert increases recognition of this high cholesterol disorder.
Who is the study for?
This trial is for clinicians who manage patients with high cholesterol. It aims to see if a computer alert helps in recognizing Familial Hypercholesterolemia, a genetic disorder causing high cholesterol.
What is being tested?
The intervention being tested is an alert-based computerized decision support system designed to assist clinicians in identifying Familial Hypercholesterolemia among patients.
What are the potential side effects?
Since this trial tests a computerized tool rather than a medication or medical procedure, there are no direct physical side effects associated with the intervention.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Frequency of documented FH diagnosis
Secondary study objectives
Mean Change in LDL-C
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: AlertExperimental Treatment1 Intervention
In the Alert phase of 18 months, an on-screen alert through the Electronic Health Record will notify the ambulatory care clinician of record that the patient has a "definite," "probable," or "possible" diagnosis of FH but has not been recognized as such.
Group II: Pre-AlertActive Control1 Intervention
In the Pre-Alert phase of 6 months, patients meeting enrollment criteria will be identified but the clinician will not be notified regarding the possible diagnosis of Familial Hypercholesterolemia.
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,670 Previous Clinical Trials
11,877,816 Total Patients Enrolled